Missouri Patent of the Month – February 2025
Humanwell Pharmaceutical US, Inc. has developed a breakthrough in kappa opioid receptor (KOR) peptide ligands with the invention of a novel tetrapeptide compound. This innovation presents a promising new class of KOR-selective agonists designed to address pain and pruritus while minimizing the adverse effects typically associated with traditional opioid medications.
The invention introduces a kappa opioid receptor peptide ligand of Formula (I), where the carefully selected D-amino acid sequence enhances receptor selectivity and potency. Unlike previous KOR agonists that failed due to side effects such as dysphoria and sedation, this novel compound aims to provide effective therapeutic benefits without compromising patient comfort and safety.
KORs are critical in modulating pain perception, mood, and immune responses. While earlier attempts at developing KOR-targeting analgesics encountered setbacks, Humanwell’s new peptide-based ligand leverages advances in molecular design to overcome these challenges. The compound’s structure not only ensures high affinity for KORs but also improves pharmacokinetic properties, making it a strong candidate for clinical application.
Beyond pain management, the invention holds potential for treating conditions such as chronic itching (pruritus), irritable bowel syndrome, and certain neurological disorders. By focusing on a selective and refined molecular approach, Humanwell aims to provide an alternative to conventional opioids, addressing the growing need for safer analgesics amid the opioid crisis.
This invention marks a significant step forward in peptide-based pharmacotherapy. As research progresses, this KOR peptide ligand may redefine treatment strategies for pain and other KOR-related conditions, offering patients relief with fewer risks and improved efficacy.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
Are you eligible?
Why choose us?
Pass an Audit?
What is the R&D Tax Credit?
The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.
Never miss a deadline again
Stay up to date on IRS processes
Discover R&D in your industry
R&D Tax Credit Preparation Services
Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.
If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.
R&D Tax Credit Audit Advisory Services
creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.
Our Fees
Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/
Choose your state
